KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Co-Diagnostics (CODX) Gains from Sales and Divestitures (2020 - 2025)

Historic Gains from Sales and Divestitures for Co-Diagnostics (CODX) over the last 6 years, with Q3 2025 value amounting to $734500.0.

  • Co-Diagnostics' Gains from Sales and Divestitures rose 961.31% to $734500.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $734500.0, marking a year-over-year increase of 961.31%. This contributed to the annual value of $1.5 million for FY2024, which is 923.79% up from last year.
  • As of Q3 2025, Co-Diagnostics' Gains from Sales and Divestitures stood at $734500.0, which was up 961.31% from $734500.0 recorded in Q2 2025.
  • Over the past 5 years, Co-Diagnostics' Gains from Sales and Divestitures peaked at $1.5 million during Q4 2024, and registered a low of $18750.0 during Q1 2024.
  • In the last 5 years, Co-Diagnostics' Gains from Sales and Divestitures had a median value of $516293.5 in 2021 and averaged $511643.9.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first soared by 152408.15% in 2021, then crashed by 7272.73% in 2024.
  • Co-Diagnostics' Gains from Sales and Divestitures (Quarter) stood at $438502.0 in 2021, then soared by 65.37% to $725166.0 in 2022, then surged by 86.73% to $1.4 million in 2023, then increased by 9.24% to $1.5 million in 2024, then tumbled by 50.34% to $734500.0 in 2025.
  • Its last three reported values are $734500.0 in Q3 2025, $734500.0 for Q2 2025, and $1.5 million during Q4 2024.